A deadly plague swept through Pharaoh Akhenaten's holy city, killing hundreds—but he refused to help. Now, mass graves of ...

The Guernsey-based investor in the life sciences sector said it invested USD5.9 million in Yarrow Bioscience, representing 0.7% of its net asset value as of November 30. RTW notes that Yarrow was ...

Environmental exposures are emerging as major contributors to autoimmune risk: Studies link air pollution, PFAS, and ...

Vyne Therapeutics is set to combine with Yarrow Bioscience in an all-stock merger. Vyne, a clinical-stage biopharmaceutical company, and Yarrow Bioscience, a clinical-stage biotechnology company said ...

An announcement from VYNE Therapeutics ( ($VYNE) ) is now available. On December 17, 2025, VYNE Therapeutics and Yarrow Bioscience announced a ...

Following closing, combined company plans to progress Yarrow’s lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating ...

“TED is 5 times more prevalent in women, and because of that, men are often overlooked for the diagnosis,” Nijm said. The ...

Two phase 3 trials evaluating a subcutaneous (SC) formulation of efgartigimod (efgartigimod alfa and hyaluronidase-qvfc ), a neonatal Fc receptor blocker, ...

Through a potential $1.37 billion deal, New York-headquartered Yarrow gains ex-China rights to a potential first-in-class ...

Secukinumab does not show greater clinical efficacy than placebo in patients with moderate-to-severe Graves' orbitopathy, ...

("GenSci"), RTW Investments, LP ("RTW"), and Yarrow Bioscience, Inc. ("Yarrow") today announced an exclusive global ex-China license agreement for GS-098, a clinical-stage, first-in-class, humanized ...

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...